Podcasts about Munshi

In this JCO Article Insights episode, Michael Hughes summarizes “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma" by Avet-Loiseau et al. published on June 09, 2025 along with an interview with author Dr Nikhil C. Munshi, MD. TRANSCRIPT Michael Hughes: Welcome to this episode of JCO Article Insights. This is Michael Hughes, JCO's editorial fellow. Today I am interviewing Dr. Nikhil Munshi on the “International Myeloma Society and International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma” by Avet-Loiseau et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. While some patients with multiple myeloma live for decades after treatment, others exhibit refractory or rapidly relapsing disease irrespective of treatment administered. We term this “high-risk myeloma.” Multiple risk stratification systems have been created, starting with the Durie-Salmon system in 1975 and evolving with the advent of novel therapeutics and novel treatment approaches. In 2015, the Revised International Staging System (R-ISS) was introduced, which incorporated novel clinical and cytogenetic markers and remained, until recently, a mainstay of risk stratification in newly diagnosed disease. Myeloma as a field has, just in the past few years, though, undergone explosive changes. In particular, we have seen groundbreaking advances not only in treatments - the introduction of anti-CD38 agents and the advent of cellular and bispecific therapies - but also in diagnostic technology and our understanding of the genetic lesions in myeloma. This has led to the proliferation of numerous trials employing different definitions of high-risk myeloma, a burgeoning problem for patients and providers alike, and has prompted attempts to consolidate definitions and terminology. Regarding cytogenetic lesions, at least, Kaiser et al's federated meta-analysis of 24 therapeutic trials, published here in the JCO in February of 2025 and recently podcasted in an interview with associate editor Dr. Suzanne Lentzsch, posited a new cytogenetic classification system to realize a shared platform upon which we might contextualize those trial results. This article we have here by Dr. Avet-Loiseau, Dr. Munshi, and colleagues, published online in early June of this year and hot off the presses, is the definitive joint statement from the International Myeloma Society (IMS) and the International Myeloma Working Group (IMWG). What is high-risk multiple myeloma for the modern era? The IMS and IMWG Genomics Workshop was held in July 2023 and was attended by international myeloma experts, collaborating to reach consensus based on large volumes of data presented and shared. The datasets included cohorts from the Intergroupe Francophone du Myélome (IFM); the HARMONY project, comprised of multiple European academic trials; the FORTE study, findings from which solidified KRd as a viable induction regimen; the Grupo Español de Mieloma Múltiple (GEM) and the PETHEMA Foundation; the German-Speaking Myeloma Multicenter Group (GMMG); the UK-based Myeloma XI, findings from which confirmed the concept of lenalidomide maintenance; Emory 1000, a large, real-world dataset from Emory University in Atlanta; the Multiple Myeloma Research Foundation Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) dataset; and some newly diagnosed myeloma cohorts from the Mayo Clinic. Data were not pooled for analyses and were assessed individually - that is to say, with clear a priori understanding of whence the data had been gathered and for what original purposes. Consensus on topics was developed based on the preponderance of data across studies and cohorts. In terms of results, substantial revisions were made to the genomic staging of high-risk multiple myeloma, and these can be sorted into three major categories: A) alterations to the tumor suppressor gene TP53; B) translocations involving chromosome 14: t(14;16) (c-MAF overexpression), t(14;20) (MAFB overexpression), and t(4;14) (NSD2 overexpression); and C) chromosome 1 abnormalities: deletions of 1p or additional copies of 1q. In terms of category A, TP53 alterations: Deletion of 17p is present in up to 10% of patients at diagnosis and is enriched in relapsed or refractory disease. This is well-documented as a high-risk feature, but the proportion of the myeloma cells with deletion 17p actually impacts prognosis. GEM and HARMONY data analyses confirmed the use of 20% clonal cell fraction as the optimal threshold value for high-risk disease. That is to say, there must be the deletion of 17p in at least 20% of the myeloma cells on a FISH-analysis of a CD138-enriched bone marrow sample to qualify as high-risk disease. TP53 mutations can also occur. Inactivating mutations appear to have deleterious effects similar to chromosomal losses, and the biallelic loss of TP53, however it occurs, portends particularly poor prognosis. This effect is seen across Myeloma XI, CoMMpass, and IFM cohorts. Biallelic loss is rare, it appears to occur in only about 5% of patients, but next-generation sequencing is nevertheless recommended in all myeloma patients. Category B, chromosome 14 translocations: Translocation t(14;16) occurs in about 2% to 3% of patients with newly diagnosed disease. In the available data, primarily real-world IFM data, t(14;16) almost always occurs with chromosome 1 abnormalities. Translocation t(4;14) occurs in about 10% to 12% of newly diagnosed disease, but only patients with specific NSD2 alterations are, in fact, at risk of worse prognosis, which clinically appears to be about one in every three of those patients. And so together, the CoMMpass and Myeloma XI data suggest that translocation t(4;14) only in combination with deletion 1p or gain or amplification of 1q correlates with worse prognosis. Translocation t(14;20) occurs in only 2% of newly diagnosed disease. Similar to translocation t(4;14), it doesn't appear to have an effect on prognosis, except if the translocation co-occurs with chromosome 1 lesions, in which case patients do fare worse. Overall, these three translocations - t(14;16), t(4;14), and t(14;20) - should be considered high-risk only if chromosome 1 aberrations are also present. In terms of those chromosome 1 aberrations, category C, first deletions of 1p: Occurring in about 13% to 15% of newly diagnosed disease, deletion 1p eliminates critical cell checkpoints and normal apoptotic signaling. In the IFM and CoMMpass dataset analyses, biallelic deletion of 1p and monoallelic deletion of 1p co-occurring with additional copies of 1q denote high-risk. In terms of the other aberration in chromosome 1 possible in myeloma, gain or amplification of 1q: This occurs in up to 35% to 37% of newly diagnosed disease. It upregulates CKS1B, which is a cyclin-dependent kinase, and ANP32E, a histone acetyltransferase inhibitor. GEM and IFM data suggest that gain or amplification of 1q - there was no clear survival detriment to amplification - is best considered as a high-risk feature only in combination with the other risk factors as above. Now, in terms of any other criteria for high-risk disease, there remains one other item, and that has to do with tumor burden. There has been a consensus shift, really, in both the IMS and IMWG to attempt to develop a definition of high-risk disease which is based on biologic features rather than empirically observed and potentially temporally dynamic features, such as lactate dehydrogenase. Beta-2 microglobulin remains an independent high-risk indicator, but care must be taken when measuring it, as renal dysfunction can artificially inflate peripheral titers. The consensus conclusion was that a beta-2 microglobulin of at least 5.5 without renal failure should be considered high-risk but should not preclude detailed genomic profiling. So, in conclusion, the novel 2025 IMS-IMWG risk stratification system for myeloma is binary. It's either high-risk disease or standard-risk disease. It's got four criteria. Number one, deletion 17p and/or a TP53 mutation. Clonal cell fraction cut-off, remember, is 20%. Or number two, an IGH translocation - t(4;14), t(14;16), t(14;20) - with 1q gain and/or deletion of 1p. Or a monoallelic deletion of 1p with 1q additional copies or a biallelic deletion of 1p. Or a beta-2 microglobulin of at least 5.5 only when the creatinine is normal. This is a field-defining work that draws on analyses from across the world to put forward a dominant definition of high-risk disease and introduces a new era of biologically informed risk assessment in myeloma. Now, how does this change our clinical approach? FISH must be performed on CD138-enriched samples and should be performed for all patients. Next-generation sequencing should also be performed on all patients. Trials will hopefully now begin to include this novel definition of high-risk multiple myeloma. It does remain to be seen how data from novel therapeutic trials, if stratified according to this novel definition, will be interpreted. Will we find that therapies being evaluated at present have differential effects on myelomas with different genetic lesions? Other unanswered questions also exist. How do we go about integrating this into academic and then community clinical practice? How do we devise public health interventions for low-resource settings? To discuss this piece further, we welcome the esteemed Dr. Nikhil Munshi to the podcast. Dr. Munshi is a world-renowned leader in multiple myeloma and the corresponding author on this paper. As Professor of Medicine at Harvard Medical School, Director of the Multiple Myeloma Effector Cell Therapy Unit, and Director of Basic and Correlative Science at the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute, he has presided over critical discoveries in the field.  Thank you for joining us, Dr. Munshi. Dr. Nikhil Munshi: Oh, it's my pleasure being here, Michael, to discuss this interesting and important publication. Michael Hughes: I had a few questions for you. So number one, this is a comprehensive, shall we say, monumental and wide-ranging definition for high-risk myeloma. How do you hope this will influence or impact the ways we discuss myeloma with patients in the exam room? And how do we make some of these components recommended, in particular next-generation sequencing, feasible in lower-resource settings? Dr. Nikhil Munshi: So those are two very important questions. Let's start with the first: How do we utilize this in our day-to-day patient care setting? So, as you know well, we have always tried to identify those patients who do not do so well with the current existing treatment. And for the last 30 years, what constitutes a myeloma of higher risk has continued to change with improvement in our treatment. The current definition basically centers around a quarter of the patients whose PFS is less than 2 to 3 years. And those would require some more involved therapeutic management. So that was a starting point of defining patients and the features. As we developed this consensus amongst ourselves - and it's titled as “International Myeloma Society, International Myeloma Working Group Consensus Recommendation” - this IMS-IMWG type of recommendation we have done for many years, improvising in various areas of myeloma care. Now, here, we looked at the data that was existing all across the globe, utilizing newer treatment and trying to identify that with these four-drug regimens, with transplant and some of the immunotherapy, which group of patients do not do as well. And this is where this current algorithm comes up. So before I answer your question straight, “How do we use it?” I might like to just suggest, “What are those features that we have identified?” There are four features which constitute high-risk disease in the newer definition. Those with deletion 17p with 20% clonality and/or TP53 mutation. Number two, patients with one of the translocations - t(4;14), t(14;16), or t(14;20) - co-occurring with 1q amplification or deletion 1p32. And that's a change. Previously, just the translocation was considered high-risk. Now we need a co-occurrence for it to be called high-risk. The third group is patients having biallelic deletion 1p32 or monoallelic deletion 1p32 along with 1q amplification. And finally, patients with high beta-2 microglobulin, more than or equal to 5.5 mg/dL, with normal creatinine less than 1.2 mg/dL. And the question, “How do we use this?” There are multiple areas where we incorporate high-risk features in our treatment algorithm. One of the first areas is where we would consider the induction regimen. If a patient has a high-risk disease, we would definitely consider a four-drug regimen rather than a three-drug regimen, although we are beginning to incorporate four-drug for all groups. That's one important thing. Number two, those are the patients where we do consider consolidation with transplant or maybe in the new world, considering some of the immunotherapeutic consolidation more early or more aggressively. Number three, these are the patients who get a little bit more maintenance therapy. So normally, lenalidomide might end up being our standard maintenance regimen. In patients who have high-risk disease, we incorporate either addition of daratumumab or the anti-CD38 targeting antibody and/or addition of proteasome inhibitor, either bortezomib or carfilzomib. So you would have multi-drug maintenance therapy in these patients. And in high-risk patients, we follow them with maintenance longer periods of time. One very critically important point to keep in mind is that to get the better outcome in high-risk disease, we must try to get them into MRD negativity because there is clear data that patients who do achieve MRD negativity, despite having high-risk disease, have a much superior outcome. They become near to standard-risk disease. And so, in high-risk patients, I would try to do whatever various options I have to try and get them into MRD-negative status. And when these patients relapse, we do not wait for the classic progression criteria to be met before we intervene. We would propose and suggest that we intervene earlier before the disease really blasts off. And so there are a number of areas in our setting where this high-risk definition will help us intervene appropriately and also with appropriate aggressiveness to achieve better outcome, to make this similar to standard-risk disease. Michael Hughes: Thank you, Dr. Munshi. And thoughts on how to really integrate this not only into academic centers but also lower-resource settings? Dr. Nikhil Munshi: So that's a very important question, Michael. And when we were developing this consensus, we were very cognizant of that fact. So wherever available, I think we are recommending that over a period of next 2, 3, 5 years, we should begin to switch over to sequencing-based methods because two components of this definition, one is TP53 mutation, which we cannot do without sequencing, and also reliably detecting deletion 1p requires sequencing-based method. So in the low-resource countries - and there are many in this world, and also even in our own country, patients may not be able to afford it - the older method with FISH or similar such technology, which is more affordable, is also acceptable for current time. They may miss a very small number of patients, maybe 2% to 3%, where these finer changes are not picked up, but a majority of this would be captured by them. So the current practice might still be applicable with some limitation in those patient populations, and that's what we would recommend. What is happening, fortunately, is that actually sequencing-based method is becoming cheaper. And in many centers, it is cheaper to do the sequencing rather than to do the FISH analysis. And so my hope is that even in low-resource centers, sequencing might be more economical in the end. It's, I think, the access to technology, which is a little bit limited currently, but it's hopefully becoming available soon. Michael Hughes: Thank you, Dr. Munshi. And staying for a minute and looking at the multiple myeloma subsets which might be missed by this really still very broad-ranging high-risk definition, at least by prior risk stratification systems, right, there is this group of patients who have standard-risk cytogenetics by R-ISS or R2-ISS, but they have primary refractory disease or they relapse early. We call these, as you are well aware, functionally high-risk disease. What proportion of previously FHR, functionally high-risk, myeloma patients do you expect to be captured by this novel definition? Dr. Nikhil Munshi: So I think the newer definition - and we can look at it both ways, but the newer definition should capture most of the functionally high-risk definition. To put it differently, Michael, there are patients who we know are, as you mentioned, functionally high-risk. Those are the patients who might have plasma cell leukemia, those who might have extramedullary disease, those who might not respond to our four-drug induction. If you don't respond to the four-drug induction, almost by definition, they are high-risk. However, a majority of them have one of the abnormalities that we are describing here. There would be a very small proportion which may not have. And if they do not have, we know one of the important components of this definition here is also that the genome, we know, keeps on evolving. So there may be a very small clone with the high-risk feature which was not obvious in the beginning. Following treatments or following relapse, that clone predominates, and now the patient's disease becomes high-risk.  So the definition would incorporate or would capture these functional high-risk patients, but as you said, in countries where resources are not available, using this functional high-risk would also be helpful and advantageous. Sometimes LDH ends up being a high-risk. In our studies, LDH has not come out to be high-risk anymore because the features we are describing captures most of those patients, but those alternatives, older, can still be considered if other newer techniques are not available. Michael Hughes: Got you. And in terms of these older definitions, yes, that incorporate tumor burden, these empirical observations about how myeloma presents, do you foresee any additional tumor burden indicators being added to future definitions of high-risk disease? Or do you instead see this particular definition as a major waypoint on the journey towards a fully biologically grounded definition of high-risk disease? Dr. Nikhil Munshi: I think your second part is what is going to happen. I think the tumor burden-related definition is being now replaced by the biological or genomic-based definition. And I think at some point, it will be quite fully replaced. One component not here, and it is because one thing, we don't have enough data; number two, we don't know how it will pan out, is also the influence of the microenvironment on the risk definition. For example, the immune system, the immune function, etc. But not enough data exists to suggest how it would change the current definition. So in future, would a definition be totally genomic or it could be more integrative? And my personal guess is that it would be more integrative and that some immune features might come into the picture, especially now that we are using immune-based therapy as a very important component of treatment - CAR T-cells, bispecific, and antibody-based treatments. What role the immune system plays in either supporting tumor or what role suppression of the anti-tumor immunity plays? They all will be important how patient outcomes end up being, and which in turn could translate into how patient's risk stratification might happen. So I think the older tumor burden-related definitions probably will become things of the past. What we have currently proposed and consensus developed is the new path forward, and over time, some microenvironmental influences, if defined and found to be important, may get some more incorporation if it compares favorably with the genomic features. Michael Hughes: Thank you, Dr. Munshi for that enlightening response.  To conclude the podcast, I'd like to look to the future and to the immediate future, what are the next steps for high-risk disease definition between now and discussing an integrated genomic-microenvironment-based definition? Will we see attempts to refine? Will we see a multi-level system, things like this? Dr. Nikhil Munshi: Yeah, so I think the current definition will be here to stay for the next 10 years or so. I think this has been developed using a large amount of data, so we do believe that this will remain fine. It has been validated now within the last six months by a few of the other studies. So there won't be a quick change. But we will try to, all of us will try to innovate. And as you very rightly bring up, the areas of research would include looking at the expression or transcriptomic component. Does that matter? And we do believe a small number of patients will have transcriptomic changes, not looked at the DNA changes, and may play a role. There are newer components, so long non-coding RNA, for example, is going to be an important component to look at, how it impacts the disease outcome, etc. There are also some of the proteomic-related changes which may become important in our studies. And then as we discussed, microenvironment and immunological changes. So these are the future areas of ongoing research where we all should collect data, and then in the next 5 to 10 years, we'll have another group meeting to see has anything changed or any of the features have become more important.  Most of the time, some of the older features are lost because they are not as critically high-risk, and the newer features come in. And so the historical background for just one second, there was a time when chromosome 13 was considered a high-risk disease. We now don't even mention it because it's not high-risk. The newer treatments have improved the outcome. t(4;14) used to be a high-risk disease. Now by itself today, in this definition by itself is not; it needs to be with something else. And so I think this is a great sign of progress. As we improve the treatment and outcomes, some of the features will become less important, new features will come up, and we'll need to keep on evolving with time and with technology and make it better for patients. Michael Hughes: Thank you so much, Dr. Munshi, for your wisdom, for your sagacity, for your historical perspective as well.  Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries. And be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Today my guest is environmental scholar, historian and biographer Ramachandra Guha. He is the author of a number of books, including a two-volume biography of Gandhi and the award-winning book “India After Gandhi.” We talked about his latest book, "Speaking with Nature: The Origins of Indian Environmentalism.” We spoke about global versus local commons, bottom up approach to environmentalism in India, urbanization, economic growth and technological progress and much more. Recorded May 7th, 2025. Read a full transcript enhanced with helpful links. Connect with Ideas of India Follow us on X Follow Shruti on X Follow Ram on X Click here for the latest Ideas of India episodes sent straight to your inbox. Timestamps 00:00:00 - Intro 00:01:08 - Speaking with Nature 00:08:42 - Unquiet Woods 00:38:29 - Science and Progress of Environmentalism  00:47:33 - Radhakamal Mukerjee 00:55:06 - K. M. Munshi 01:03:38 - Technological Progress and Tradeoffs 01:11:22 - Jayaprakash Narayan 01:19:39 - Outro

Mirza Hadi Ruswa recounts in the preface of his novel, Umrao Jaan Ada, how he came to write the story of a courtesan from Lucknow.  His friend Munshi Ahmad Hussain had rented a floor in a chowk in Lucknow and this is where he organised mushairas for his friends. Next to his house lives a most mysterious woman who is never seen, but sometimes late at night she can be heard singing. Once at a mushaira hosted by Munshi, Ruswa recites a couplet and a soft voice from next door exclaims, “wah! Wah!”. The mysterious lady invites Ruswa to her home and turns out to be Umrao Jaan Ada who Ruswa had known many years ago. She then proceeds to narrate her story to Ruswa, which then became the famous novel, Umrao Jaan Ada. मिर्ज़ा हादी रुसवा अपने उपन्यास उमराव जान अदा की प्रस्तावना में बताते हैं कि कैसे उन्होंने लखनऊ की एक तवायफ़ की कहानी लिखी। उनके दोस्त मुंशी अहमद हुसैन ने लखनऊ के एक चौक में एक घर किराये पर लिया था। यहाँ वो अपने दोस्तों के लिए मुशायरे आयोजित करते थे। उनके घर के बगल में एक बहुत ही रहस्यमयी महिला रहती है जो कभी दिखाई नहीं देती, लेकिन कभी-कभी देर रात को उसे गाते हुए सुना जा सकता है। एक बार मुंशी द्वारा आयोजित एक मुशायरे में रुसवा एक शेर पढ़ते हैं और बगल के दरवाजे से एक धीमी आवाज़ में आवाज़ आती है, "वाह! वाह!"। रहस्यमयी महिला रुसवा को अपने घर बुलाती है और पता चलता है की वह उमराव जान अदा है जिसे रुसवा कई सालों पहले मिले थे। उमराव जान अपनी कहानी रुसवा को अपनी कहानी सुनाती है।कहानी बन जाती है उर्दू का पहला उपन्यास- उमराव जान अदा।

From one of the world's leading historians comes the first substantial study of environmentalism set in any country outside the Euro-American world. By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In Speaking with Nature: The Origins of Indian Environmentalism (Yale UP, 2024), Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context.  In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanization and industrialization. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full-stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. About the Author: Ramachandra Guha is the author of many books, including India After Gandhi: The History of the World's Largest Democracy and Gandhi: The Years That Changed the World, 1914–1948. Guha's awards include the Leopold-Hidy Prize of the American Society of Environmental History, the Elizabeth Longford Prize for Historical Biography, and the Fukuoka Prize for contributions to Asian studies. He lives in Bangalore. About the Host: Stuti Roy has recently graduated with an MPhil in Modern South Asian Studies at the University of Oxford.  Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

From one of the world's leading historians comes the first substantial study of environmentalism set in any country outside the Euro-American world. By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In Speaking with Nature: The Origins of Indian Environmentalism (Yale UP, 2024), Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context.  In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanization and industrialization. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full-stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. About the Author: Ramachandra Guha is the author of many books, including India After Gandhi: The History of the World's Largest Democracy and Gandhi: The Years That Changed the World, 1914–1948. Guha's awards include the Leopold-Hidy Prize of the American Society of Environmental History, the Elizabeth Longford Prize for Historical Biography, and the Fukuoka Prize for contributions to Asian studies. He lives in Bangalore. About the Host: Stuti Roy has recently graduated with an MPhil in Modern South Asian Studies at the University of Oxford.  Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

From one of the world's leading historians comes the first substantial study of environmentalism set in any country outside the Euro-American world. By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In Speaking with Nature: The Origins of Indian Environmentalism (Yale UP, 2024), Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context.  In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanization and industrialization. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full-stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. About the Author: Ramachandra Guha is the author of many books, including India After Gandhi: The History of the World's Largest Democracy and Gandhi: The Years That Changed the World, 1914–1948. Guha's awards include the Leopold-Hidy Prize of the American Society of Environmental History, the Elizabeth Longford Prize for Historical Biography, and the Fukuoka Prize for contributions to Asian studies. He lives in Bangalore. About the Host: Stuti Roy has recently graduated with an MPhil in Modern South Asian Studies at the University of Oxford.  Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies

From one of the world's leading historians comes the first substantial study of environmentalism set in any country outside the Euro-American world. By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In Speaking with Nature: The Origins of Indian Environmentalism (Yale UP, 2024), Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context.  In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanization and industrialization. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full-stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. About the Author: Ramachandra Guha is the author of many books, including India After Gandhi: The History of the World's Largest Democracy and Gandhi: The Years That Changed the World, 1914–1948. Guha's awards include the Leopold-Hidy Prize of the American Society of Environmental History, the Elizabeth Longford Prize for Historical Biography, and the Fukuoka Prize for contributions to Asian studies. He lives in Bangalore. About the Host: Stuti Roy has recently graduated with an MPhil in Modern South Asian Studies at the University of Oxford.  Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/intellectual-history

From one of the world's leading historians comes the first substantial study of environmentalism set in any country outside the Euro-American world. By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In Speaking with Nature: The Origins of Indian Environmentalism (Yale UP, 2024), Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context.  In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanization and industrialization. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full-stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. About the Author: Ramachandra Guha is the author of many books, including India After Gandhi: The History of the World's Largest Democracy and Gandhi: The Years That Changed the World, 1914–1948. Guha's awards include the Leopold-Hidy Prize of the American Society of Environmental History, the Elizabeth Longford Prize for Historical Biography, and the Fukuoka Prize for contributions to Asian studies. He lives in Bangalore. About the Host: Stuti Roy has recently graduated with an MPhil in Modern South Asian Studies at the University of Oxford.  Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/south-asian-studies

By the canons of orthodox social science, countries like India are not supposed to have an environmental consciousness. They are, as it were, “too poor to be green.” In his new book, Speaking with Nature, Ramachandra Guha challenges this narrative by revealing a virtually unknown prehistory of the global movement set far outside Europe or America. Long before the publication of Rachel Carson's Silent Spring and well before climate change, ten remarkable individuals wrote with deep insight about the dangers of environmental abuse from within an Indian context. In strikingly contemporary language, Rabindranath Tagore, Radhakamal Mukerjee, J. C. Kumarappa, Patrick Geddes, Albert and Gabrielle Howard, Mira, Verrier Elwin, K. M. Munshi, and M. Krishnan wrote about the forest and the wild, soil and water, urbanisation and industrialisation. Positing the idea of what Guha calls “livelihood environmentalism” in contrast to the “full stomach environmentalism” of the affluent world, these writers, activists, and scientists played a pioneering role in shaping global conversations about humanity's relationship with nature. Spanning more than a century of Indian history, and decidedly transnational in reference, this book offers rich resources for considering the threat of climate change today. In this episode of BIC Talks, Ramchandra Guha is in conversation with Harini Nagendra. This is an excerpt from a conversation that took place in the BIC premises in September 2024. Subscribe to the BIC Talks Podcast on your favorite podcast app! BIC Talks is available everywhere, including Apple Podcasts, Spotify, Google Podcasts, Castbox, Overcast, Audible, and Amazon Music.

IANR 2445 110924 Line Up 4-6pm INTERVIEWS Here's the guest line-up for Sat, November 9, 2024 from 4 to 6pm CST on Indo American News Radio, a production of Indo American News (www.IndoAmerican-news.com). We are on 98.7 FM and you can also listen by downloading the masalaradio app. By Monday, hear the recorded show on Podcast uploaded on Spotify, Apple Podcasts, Pocket Casts, Radio Public and Breaker. We have 5 years of Podcasts and have had thousands of hits. TO SUPPORT THE SHOW, SELECT FOLLOW ON OUR FREE PODCAST CHANNEL AND YOU'LL BE NOTIFIED OF NEW UPDATES. 4:20 pm Most of us from the Old Country are familiar with how pervasive corruption is in all walks of life and some have even fled to the US after being stymied in their dreams back home. Fast forward many years and we are finding that corruption is rife in the US too, just better hidden. It becomes the job of local law enforcement, like the Harris County District Attorney's office, to ferret corruption out and prosecute the offenders. To tell us more about how this is done, we are joined by Asst. District Attorney Kimberley Smith who has been working in the Public Corruption Division. 4:50 pm A post-election analysis of the national, state and local elections by Jawahar Malhotra, Chetan Dave, Sridhar Kotha, Imtiaz Munshi and Kapil Sharma and what moves you may expect in the future. Also stay tuned in for news roundup, views, sports and movie reviews. TO BE FEATURED ON THE SHOW, OR TO ADVERTISE, PLEASE CONTACT US AT 713-789-NEWS or 6397 or at indoamericannews@yahoo.com Please pick up the print edition of Indo American News which is available all across town at grocery stores. Also visit our website indoamerican-news.com which gets 90,000+ hits to track all current stories. And remember to visit our digital archives from over 16 years.  Plus, our entire 43 years of hard copy archives are available in the Fondren Library at Rice University. --- Support this podcast: https://podcasters.spotify.com/pod/show/indo-american-news-radio/support

It was in 1978 that Ms Karuna Munshi had her first darshan of Bhagawan. Recalling that moment she says, “He had cast His divine spell on me and my soul had been awakened in the most sacred and pure way.” Soon after she longed to be His student and did live that dream. In this episode of OMS she picks one of her unforgettable moments she experienced when Bhagawan visited the Anantapur campus way back in the early 1980s. That short and sweet moment with Swami continues to be the source of her energy and inspiration as she continues to serve in His mission, currently as the Director of Sri Sathya Sai Vidya Vahini.

In this episode of 21 Min. Pharma Edge powered by Game of Pharma, we are thrilled to have Dr. Vikram A. Munshi, Founder of WhiteSpace Consulting & Capability Building & Author of Find Your WhiteSpace. In this episode of 21 Min Pharma Edge, learn how to find your deep purpose, create inner calm, and transform your life in today's fast-paced world. Unlock insights that go beyond technical skills and lead to true self-transformation. Listen now to start your journey to clarity and peace!Available on Spotify, Gaana, JioSaavn, Amazon Music, and Apple Podcasts. Dr. Vikram's LinkedIn: https://www.linkedin.com/in/dr-vikram-a-munshi/Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/Visit our website for the latest updates in pharma and to stay informed about future episodes: https://gameofpharma.inFollow us on social media-Instagram: https://www.instagram.com/gameofpharma/LinkedIn: https://www.linkedin.com/company/game-of-pharma/YouTube: https://www.youtube.com/channel/UCGLNWWSCYZz3WbY77gencpw

Are you the best kept secret on the internet? You're incredible at what you do, now you just need more people to know about you. That's where quizzes and Helen come in.Helen is an online business strategist and trained quiz funnel expert with over 15 years experience in strategy & entrepreneurship. She helps businesses generate consistent high quality leads using the power of positive interactive quizzes. She is all about creating a list of buyers rather than lurkers and doing lead generation with heart.She's supported entrepreneurs like Holly-Marie Haynes to build engaged communities ready to buy - "Helen's strategy tips helped me create a lead magnet that now has an average 80% conversion rate and 70% email open rate. The results I am seeing to grow my community are mind-blowing. Plus Helen made the process fun and enjoyable"She's also a country music loving Brit! Usually found with a messy ginger bun, eating anything spicy and playing Korfball.So if you're ready to ditch scare marketing and boring freebies and get results like Holly then you need a quiz in your business. She offers done for you quiz writing services and also supports people to create their own quizzes through The Quiz Academy.www.helenmunshi.comhttps://www.facebook.com/groups/139117106726077/https://www.instagram.com/helenmunshi/https://www.pinterest.com/thestartupstudio/https://www.linkedin.com/in/helenmunshiTimestamps:[2:00] How did you transition from Pinterest marketing to the path you've taken to end up where you are now?[6:00] What kind of journey would a typical client of yours go on?[10:00] What sort or results do you see for these businesses?[12:10] How does it translate into sales?[14:50] What app do you use and what does it cost to use your services?[19:00] Would you ever go back to the corporate world? And how do you get the interaction you do miss from that environment?[22:55] What propelled you to change from focusing on Pinterest?[25:20] All in the surname! What question does Helen have for Nick on the next Fireside Chats[28:00] Holiday brain and mindset[30:00] Where are you taking the business?[34:45 ] If your business had a character or personality who would it be or what would that look like?———————————————Subscribe to Tricres! https://www.youtube.com/channel/UCX0EUHMC2CckN6amdXL2F3Q?sub_confirmation=1We interview entrepreneurs at the beginning, middle, and end of their businesses so if you're a coach and consultant get inside the head of business owners and gain their insights and driving forces.Join our growing family and community of business coaches and consultants! If you passion is about making it happen for SMEs you need to listen to our podcast with business owners from around the world.Find our other podcasts HERE at:https://tricres.com/podcasts/Want to join us for our next Escape 9 to 5 Live Event to become a business coach and consultant or to enhance your existing coaching and consulting business? Find out more and sign up for our free event here: https://tricres.ac-page.com/9-to-5

Are you the best kept secret on the internet? You're incredible at what you do, now you just need more people to know about you. That's where quizzes and Helen come in.Helen is an online business strategist and trained quiz funnel expert with over 15 years experience in strategy & entrepreneurship. She helps businesses generate consistent high quality leads using the power of positive interactive quizzes. She is all about creating a list of buyers rather than lurkers and doing lead generation with heart.She's supported entrepreneurs like Holly-Marie Haynes to build engaged communities ready to buy - "Helen's strategy tips helped me create a lead magnet that now has an average 80% conversion rate and 70% email open rate. The results I am seeing to grow my community are mind-blowing. Plus Helen made the process fun and enjoyable"She's also a country music loving Brit! Usually found with a messy ginger bun, eating anything spicy and playing Korfball.So if you're ready to ditch scare marketing and boring freebies and get results like Holly then you need a quiz in your business. She offers done for you quiz writing services and also supports people to create their own quizzes through The Quiz Academy.www.helenmunshi.comhttps://www.facebook.com/groups/139117106726077/https://www.instagram.com/helenmunshi/https://www.pinterest.com/thestartupstudio/https://www.linkedin.com/in/helenmunshiTimestamps:[2:00] How did you transition from Pinterest marketing to the path you've taken to end up where you are now?[6:00] What kind of journey would a typical client of yours go on?[10:00] What sort or results do you see for these businesses?[12:10] How does it translate into sales?[14:50] What app do you use and what does it cost to use your services?[19:00] Would you ever go back to the corporate world? And how do you get the interaction you do miss from that environment?[22:55] What propelled you to change from focusing on Pinterest?[25:20] All in the surname! What question does Helen have for Nick on the next Fireside Chats[28:00] Holiday brain and mindset[30:00] Where are you taking the business?[34:45 ] If your business had a character or personality who would it be or what would that look like?———————————————Subscribe to Tricres! https://www.youtube.com/channel/UCX0EUHMC2CckN6amdXL2F3Q?sub_confirmation=1We interview entrepreneurs at the beginning, middle, and end of their businesses so if you're a coach and consultant get inside the head of business owners and gain their insights and driving forces.Join our growing family and community of business coaches and consultants! If you passion is about making it happen for SMEs you need to listen to our podcast with business owners from around the world.Find our other podcasts HERE at:https://tricres.com/podcasts/Want to join us for our next Escape 9 to 5 Live Event to become a business coach and consultant or to enhance your existing coaching and consulting business? Find out more and sign up for our free event here: https://tricres.ac-page.com/9-to-5

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है।  गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद  Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है।  गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद  Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को बखूबी चित्रित करता है। इसकी कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए हताश प्रयास करता है। उपन्यास का मुख्य संघर्ष होरी की ज़मीन को बचाने की उसकी सख्त इच्छा से उपजता है। वह कर्ज से दबा हुआ है और जमींदार उसे लगातार परेशान करता है। अपनी साख बनाए रखने और खुद को इज्जतदार साबित करने के लिए, होरी किसी भी हद तक जाने को तैयार है। वह मेहनत करता है, कर्ज लेता है, और यहां तक ​​कि अपनी बेटी की शादी भी देरी से कर देता है, बस उम्मीद है कि किसी तरह वो अपनी जमीन बचा सकेगा। लेकिन परिस्थितियां उसके खिलाफ साजिश करती हैं। जमींदार के दबाव, कर्ज के बोझ और अनिश्चितता के चलते, होरी को अंततः अपनी ज़मीन बेचनी पड़ती है। यह घटना उसे अंदर से तोड़ देती है। गोदान सिर्फ होरी की कहानी नहीं है, बल्कि पूरे भारतीय ग्रामीण समाज का दर्पण है। यह उपन्यास गरीबी, शोषण, और समाज की जड़ता को उजागर करता है। साथ ही, यह मानवीय संघर्ष, त्याग, और उम्मीद की कहानी भी बयां करता है। उपन्यास के कुछ प्रमुख बिंदु: गांव और शहर का कंट्रास्ट: गोदान दो कहानियों का संगम है - पहली, गाँव की ज़िंदगी की कहानी और दूसरी, शहर की ज़िंदगी की कहानी। ये दोनों कहानियां एक-दूसरे से जुड़ी हुई हैं और सामाजिक असमानता का गहरा चित्रण करती हैं। पात्रों का जटिल चित्रण: होरी के अलावा, उपन्यास में कई अन्य पात्र भी हैं, जिन्हें प्रेमचंद ने बारीकी से चित्रित किया है। हर पात्र की अपनी उम्मीदें, ख़्वाहिशें और संघर्ष हैं, जो कहानी को और भी ज़्यादा गहराई देते हैं। सामाजिक मुद्दों का चित्रण: गोदान ग्रामीण समाज से जुड़े कई सामाजिक मुद्दों को उजागर करता है, जैसे गरीबी, भू-स्वामित्व, कर्ज, जाति व्यवस्था, और महिलाओं की स्थिति। मानवीय मूल्यों का चित्रण: उपन्यास भले ही कठोर सच्चाई को दर्शाता है, लेकिन यह मानवीय मूल्यों का भी उत्थान करता है। होरी की मेहनत, ईमानदारी, और त्याग जैसे गुण पाठकों को प्रेरित करते हैं। गोदान, प्रेमचंद का एक अविस्मरणीय उपन्यास है, जो भारतीय ग्रामीण जीवन की कठोर वास्तविकता, सामाजिक असमानता और मानवीय संघर्षों को चित्रित करता है। कहानी होरी नामक एक गरीब किसान के इर्द-गिर्द घूमती है, जो अपनी जमीन को बचाने के लिए जद्दोजहद करता है। गोदान न सिर्फ एक मनोरंजक उपन्यास है, बल्कि यह भारतीय समाज की सामाजिक, आर्थिक और राजनीतिक वास्तविकता का एक गहरा दर्शन भी प्रस्तुत करता है। यह उपन्यास आज भी प्रासंगिक है और पाठकों को सोचने पर मजबूर कर देता है। लेखक - मुंशी प्रेमचंद Writer - Munshi Premchand स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno/ https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

In this episode, we chat with Dr. Adeel Munshi and Dr. Fatima Vindhani, the powerhouse couple behind The Modern Dr. Combining their lived experience with infertility and their deep passion for acupuncture and Traditional Chinese Medicine (TCM), they have created a thriving business helping couples across Perth. Dr. Adeel Munshi, a Registered Acupuncturist and multi-modal practitioner, specialises in women's health, fertility, mental health, and more. After a challenging fertility journey with his wife, Dr. Adeel discovered the profound benefits of TCM and acupuncture. Their success with these therapies led him to pursue a BSc degree in Acupuncture from the Northern College of Acupuncture in York. Now, he dedicates his practice to treating the root causes of ailments and not just the symptoms, aiming to bring holistic healing to his patients. Dr. Fatima Vindhani, trained in the United Kingdom, brings a wealth of knowledge and experience as a General Practitioner, Cosmetic Doctor, and Integrative Practitioner. Dr. Fatima enhances the holistic approach of The Modern Dr, providing comprehensive care to their clients. Together, Dr. Adeel and Dr. Fatima share their inspiring journey from personal struggles with infertility to establishing a successful practice that empowers and supports others on similar paths. Tune in to hear how they transformed their pain into purpose and learn about the unique integrative treatments they offer at The Modern Dr. Don't miss this heartfelt and informative episode that celebrates resilience, holistic health, and the power of never giving up.This episode is proudly supported byhttps://www.themoderndr.com.au/@themoderndr.perth@dradeelmunshi

EP 134 - [Part 3 of 3 quiz mini-series]  Create quizzes that generate thousands of ready-to-buy leads. Sarah chats with her Quiz Coach, Helen Munshi, to clarify key quiz funnel aspects you need to remember when making your own branded quizzes as part of your content marketing strategy. Get Helen's free video training below. + Don't forget to take Sarah's new “Are you Ready to Improve Your Content Strategy”? QUIZ for actionable tips to help improve your company's content at link below.    Get Helen's Free Quiz Video Training to get thousands of ready-to-buy leads at https://helenmunshi.lpages.co/css-the-qa-opt-in-to-lightbulb-sarah-panus/ .      Take Sarah's FREE QUIZ: Ready to Improve Your Content Strategy?   Discover which content makeover will boost your brand's success! Take this 40-second QUIZ to find your "home" makeover show match and get a content makeover plan to help you attract customers & drive better business results.  https://www.tryinteract.com/share/quiz/65c650923a654f0015bbd704      SHOW NOTES: https://www.podpage.com/marketing-with-empathy/blog/branded-quiz-tips-quiz-coach-helen-munshi-episode-134/       SLACK COMMUNITY: JOIN free Marketing With Empathy® Slack community to connect and network with other brand storytelling pros, like yourself at https://view.flodesk.com/pages/63f2abe2a48787c3c5ff62ab     Learn more about your ad choices. Visit megaphone.fm/adchoices

In 1877 Queen Victoria took on the title Empress of India, a nation which she undoubtedly had close to her heart. Yet, under her reign and that of her successors, India was exploited. At the same time, she takes Abdul Karim, known as the Munshi, into her court. Many of her courtiers despised this Indian man and his influence, but Victoria stuck by him. Undoubtedly, Empire was central to Victoria and she saw it as a force for good, but how do we see that and the rest of her reign now? Listen as William and Anita discuss Victoria's final years and her legacy. Twitter: @Empirepoduk Email: empirepoduk@gmail.com Goalhangerpodcasts.com Assistant Producer: Anouska Lewis Producer: Callum Hill Exec Producer: Neil Fearn Learn more about your ad choices. Visit podcastchoices.com/adchoices

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/MGG865. CME/MOC/AAPA credit will be available until December 31, 2024.Raising the BCMA Standard in Multiple Myeloma: Strategies for Enhanced Care With Potent CAR-T and Bispecific Options In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerNikhil C. Munshi, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Amgen Inc; Bristol Myers Squibb; Celgene Corporation; DCT Pfizer; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Legend Biotech; Novartis Pharmaceuticals Corporation; OncoPep, Inc.; and Takeda Pharmaceutical Company Limited.Other Financial or Material Support from OncoPep, Inc. for patents and royalties. He is a current equity holder and a scientific founder for OncoPep, Inc.Faculty/PlannerHans Lee, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerProf. Mohamad Mohty has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Grant/Research Support from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Speaker for Jazz Pharmaceuticals, Inc.Honoraria from Astellas Pharma Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Novartis AG; Pfizer; Sanofi; and Takeda Pharmaceutical Company.Faculty/PlannerKrina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This episode features Amish Munshi, Founder of RERX Fund and Capital, a seasoned professional with extensive experience in consulting, particularly within real estate and technology. Amish discusses his background, expertise, and the innovative strategies he employs in the real estate debt investing space to help individuals retire with confidence and generate consistent cash flow. Amish emphasizes the significance of debt investment in real estate, especially in California, as well as prioritizing community impact and investor relations as crucial elements of his company's growth and success.   Key Takeaways: Amish's journey from a technology background to real estate and founding RERX Fund and Capital Leveraging debt investments in real estate to preserve capital and generate consistent cash flow without the headaches of property ownership Insights into the California real estate market highlighting its potential for debt investors Transitioning from fix-and-flip projects to real estate debt The shift from one-on-one interactions to scaling up communication and outreach   More about Amish: Amish, with over 20 years of consulting expertise in real estate and technology, holds an MBA in Global Business Strategy from Rutgers University and an Information Technology Engineering degree from Mumbai University. His consulting spans diverse sectors like government, finance, insurance, pharmaceuticals, education, healthcare, banking, technology, and non-profits. Amish has spearheaded projects for renowned entities including the US Federal Government, California State Government, IBM, VISA, and others. Notable involvements include Mars Curiosity Rover with NASA's Jet Propulsion Laboratory and initiatives for Affordable Healthcare and Indian language computing localization. As a dedicated husband and father of two, Amish is now a key figure in real estate investment, aiding professionals from various fields to retire confidently while generating consistent cash flow through innovative options in real estate debt investment.   Ways to connect with Amish: http://rerxfunds.com/    Useful links and resources: https://findmoreinvestors.com/apply   Join our new capital raising community group here: https://www.facebook.com/groups/capitalraisingtalkwithcapitalraisingprosgroup   Free Trainings on “How To Raise More Capital & Find High Net-Worth Investors on Auto-Pilot”: findmoreinvestors.com/capital   Enter our monthly raffle by leaving a 5-star review and emailing a screenshot to: reviews@findmoreinvestors.com   Connect with Yakov: https://www.linkedin.com/in/yakovsavitskiy/ https://www.facebook.com/yakov.smart3   The following music was used for this media project: Music: Positive Fat Bass Intro Loop by WinnieTheMoog Free download: https://filmmusic.io/song/6093-positive-fat-bass-intro-loop License (CC BY 4.0): https://filmmusic.io/standard-license Artist website: https://linktr.ee/taigasoundprod   The following music was used for this media project: Music: Just Keep Going (Loopable) by chilledmusic Free download: https://filmmusic.io/song/7245-just-keep-going-loopable License (CC BY 4.0): https://filmmusic.io/standard-license   The following music was used for this media project: Music: Business Of Dreams by MusicLFiles Free download: https://filmmusic.io/song/9392-business-of-dreams License (CC BY 4.0): https://filmmusic.io/standard-license Artist website: https://cemmusicproject.wixsite.com/musiclibraryfiles   #realestateinvesting #capitalraising #realestate #passiveinvesting

Queen Victoria's record-setting reign is finally coming to an end - at the time of her death, she was the longest-reigning monarch in England's history! Victoria's life was filled with times of joy and periods of great sadness. She continued to be a political dynamo in her later years... but should she have been? What are the actual rights of the monarch? At the end of her life, Victoria still had a few surprises up her sleeve. Learn about another controversial companion - the Munshi - who was one her closest friends and advisors during the last years of her life, much to the chagrin of her family. Join us as we wrap up the life of Queen Victoria!

In our latest episode, I've got the incredible Helen Munshi joining us for a chat. We're diving deep into business scaling using the power of quizzes. Helen's got some real-world examples up her sleeve to show you why quizzes are the secret sauce to success. We'll also explore how these quizzes can effortlessly weave into your overall strategy and insider tips for making your quiz absolutely mind-blowing with viral potential. Helen Munshi "You're great at what you do, now it's time to tell the world so you can truly scale your business - I help entrepreneurs generate consistent high quality leads using the magic of online quizzes" Helen is an online business growth strategy and trained quiz funnel expert. She has supported entrepreneurs like Holly-Marie Haynes to build engaged communities ready to buy whose freebie now converts at 80% and a 70% email open rate. She has been supporting entrepreneurs for over 15 years and also runs a property business. She runs The Quiz Academy, a DIY programme to build your quiz funnels and full bells and whistles done for you quiz funnels. She's also a country music loving Brit! Usually found with a messy ginger bun, eating anything spicy and playing Korfball (look it up, it's a real sport!!) The Angela Henderson Online Business Show Podcast Links: Helen Munshi Website FREE TRAINING - How to add 1000s of raring to buy leads to your list with a quiz (without the tech headache or pushy marketing tactics) Action Takers MastermindAustralian Business Collaborative Facebook GroupAngela Henderson WebsiteAngela Henderson Active Business Facebook GroupAngela Henderson Facebook Business PageAngela Henderson Consulting InstagramSee omnystudio.com/listener for privacy information.

Are online quizzes the ultimate lead-generation tool? Meet Helen Munshi, owner of Helen Munshi HQ. When done right, an online quiz can generate new leads, create loyal customers, and help your small business stand out in your industry. Inject energy into your business marketing with an online quiz. Welcome to the 15{ish} Minute Coffee Chat live stream and podcast with Anna and Selena – 11 seasons of helping entrepreneurs and small business owners build more profitable businesses. Connect + Laugh + Inspire Watch the episode on YouTube: Blog Show Notes: ______ Find Helen: Facebook Instagram TikTok LinkedIn: ⁠ Toolkit: ______ Letʻs be Inbox Besties. https://annaandselena.com/email/ Find us both at www.annaandselena.com ______ Find Anna: www.nomadabout.com www.facebook.com/iamnomadabout www.instagram.com/iamnomadabout Linkedin: https://www.linkedin.com/in/annadlarson/ _______ Find Selena: www.thehauoli.com www.facebook.com/thehauoli www.instagram.com/thehauoli Linkedin: https://www.linkedin.com/in/selena-conmackie/ --- Support this podcast: https://podcasters.spotify.com/pod/show/15ishminutecoffeechat/support

Send us a Text Message.I sat down with Helen Munshi, a true expert in Quiz Marketing and Business Growth Strategy. With nearly a decade of experience, Helen's journey began in the world of entrepreneurship where she mentored young business entrepreneurs, a passion that's always been close to her heart.Today, she dedicates her expertise to helping fellow entrepreneurs flourish by scaling their lead-generation efforts. It's not just about numbers for Helen; it's about nurturing quality leads. Her secret weapon? Quizzes.In our chat, Helen unveils the pivotal role lead generation plays in business growth. She highlights the significance of genuine engagement with prospects, achieved through her innovative quiz strategies.Helen believes in personalized marketing, echoing the need for businesses to speak directly to individuals. She draws parallels with how giants like Netflix make personalized recommendations. It's about embracing this individuality.Helen's scaling journey led her to create two offers: the 'done for you' service, where she immerses herself in your business, crafting tailored lead generation strategies, and the 'done with you' Quiz Academy program, offering step-by-step guidance, coaching, and support from quiz creation to driving sales.Join us for this heartfelt conversation with Helen Munshi as she demystifies quiz-based marketing. Her journey to helping entrepreneurs enhance their lead-generation strategies and grow their businesses with heart and purpose is a fascinating one!Don't miss out on this transformative knowledge; it's time to supercharge your business – one quiz at a time!Ready to take action? Dive deeper into Helen's expertise by visiting her Free Quiz Masterclass at www.freequizmasterclass.com and unlock the keys to lead generation success!Connect with Helen:www.helenmunshi.comwww.helenmunshi.lpages.co/free-quiz-trainingInstagram @helenmunshiThank you for being a part of the Soulpreneur Scaling Stories community!LET'S CONNECT✨ Download The Secrets to Soulful Scaling Private Podcast Here

This is a popular series which offers conversations with former students of Bhagawan Baba's educational institutions. They share their precious learnings and insights from being in the proximity of Bhagawan as well as how they have been shaped as they went through the Sri Sathya Sai system of integral education.   This was part of the 'Thursday Live' offering from the Sri Sathya Sai Media Centre, Prasanthi Nilayam.

This is a popular series which offers conversations with former students of Bhagawan Baba's educational institutions. They share their precious learnings and insights from being in the proximity of Bhagawan as well as how they have been shaped as they went through the Sri Sathya Sai system of integral education.   This was part of the 'Thursday Live' offering from the Sri Sathya Sai Media Centre, Prasanthi Nilayam.

In today's episode, we got to speak to two hardworking individuals who work at NAVFAC HQ, George Mendoza and Aubrey Munshi. These NAVFAC leaders spearhead all the different facilities around the globe. Find out more about their day to day and how they make NAVFAC one of the best places to work. Listen today! #navfac #podcast 

This episode is about the wonder of feathers.  Salim Ali said that birds were “feathered bipeds.” This episode explores how feathers are marvellously adaptive to suit birds and species.  Our guest is Esha Munshi who co-founded the Feather Library, a digital project documenting feathers. Esha read a quote from this book on feathers. Episode artwork: David Clode/Unsplash   From the Feather Library website A feather lying on the ground could have belonged to any number of species of birds. The type of feather, the colour, the pattern, the markings all tell a story on how to try and identify the owner. Our founding member (Esha Munshi) came up with an idea that if we could compare the feather to an existing database it would help narrow down the options and even help pinpoint the species of the bird. But no such database is in existence for Indian bird species. In Gujarat alone we have more than 500 bird species. Trying to identify a bird based on just the feather seemed like a daunting task. So it was decided that we would try to record and document as many species as we can. It started with collecting feather samples from Road kills and photographing the feathers. All feathers were counted, measured and photographed. Species details were noted down along with the location. Our co-founding member (Sherwin Everett) works at an avian hospital in Ahmedabad. The hospital receives around 1500-2000 birds per month, mostly being pigeons, kites and crows along with a fewer other common and some rare species. A number of the birds succumb to their injuries and stress, after which their bodies are discarded to the local corporation for disposal. This was a colossal pool of data just going to waste, literally. This is the first website for documenting, identification and study of Indian Birds' flight feathers in India and one of its kind in the World. A website by the name of www.featherlibrary.com has been setup as the database for the documented feathers. It is open for all and with easy access to feather plates, data regarding the species, wingspan, number of feathers, various other measurements and location of the bird. This will be useful for ornithologists, Forest department staff,  researchers, seasoned bird watchers and even creating an interest in budding birders. The main aim is to have all of this data under one roof. Our long term goal is to expand and gradually cover all of India.   

Nishi Munshi has been an Actress, Singer, Musician and Choreographer/Dancer in the entertainment industry for 15 years. Her family traveled and performed in a music band throughout her childhood around the USA and in other countries. Growing up on stage, she has performed in over 1,000 live-stage shows singing, drumming, and dancing. She practiced Mixed Martial Arts and Tae Kwon Do which helped her land her first gig on an Indian feature film 'My Name is Khan'. Over the years, her credits in acting and music include working with: NBC, CBS, USA Network, FOX, Warner Bros., and Lifetime. Some of her fan favorite roles have been on 'Jane the Virgin', Gia on 'The Originals', 'Pretty Little Liars', and Erica Malick on FOX's 'Lethal Weapon'. She's enjoying working on her fourth video game with previous fan favorites as Devi in 'The Order 1886' and Rikki Patil in 'Days Gone' under Sony Playstation. In her independent film experience, her production team was able to sell their first feature film at AFI and obtain private funding and successful filming for which she served as an Executive Producer and took her first stab at directing scenes for the film. Being a skilled Classical (Kathak, Bharatnatiyam) and 'Bollywood' dancer, she had the opportunity to choreograph and dance with prominent artists: Shakira, Jennifer Lopez, Justin Bieber, Jason Derulo and the acclaimed Michael Jackson's Cirque ONE show.  Nishi can currently be seen on the hit show Mayor of Kingstown.  Want to watch: YouTube Meisterkhan Pod. (Please Subscribe)

For this new episode of Unlimited Features, I'm pleased to introduce you to Nabeelah Munshi, founder of Bloom Marketing Agency. Born and raised in Pakistan, Nabeelah grew up with a distinctive role model… looking up to her Disney childhood hero Hanna Montana. For the American Dream to come true, she knew she had to study and work hard and so she did! Strong of life experiences in 6 countries by the age of 26, she's now an emerging successful, independent young woman who manages business accounts from one continent to the other running Branding strategies and Media campaigns for clients from US to Europe and UAE.

Finding new leads is a sure fire way to grow your business…one amazing way to generate leads is through quiz creation and we have an amazing guest today to help you learn all about it. Helen is an online business growth strategist, trained quiz funnel expert with over a decade of experience. She helps entrepreneurs generate consistent high quality leads using the magic of online quizzes. She went from struggling on a charity sector wage to over 6 figures running multiple businesses. Her success is all down to getting her audience to find her, love her and buy from her through the power of quizzes. Helen is an advocate for ditching scare marketing and boring freebies to focus on positive empathetic marketing. She's a country music loving Brit! Usually found with a messy ginger bun, eating anything spicy and playing Korfball (look it up, it's a real sport!!).   In this episode, you will learn:  Different types of quizzes & why to use them How to attract new clients with quizzes  Top tips when creating a quiz   Connect with Helen: www.helenmunshi.com https://www.instagram.com/helenmunshi/     Links Mentioned in this Episode:  What's your next best move to build a profitable and purposeful business you love?: www.helenmunshi.com/quiz   Other Resources:  Want to learn how to become a virtual assistant? Sign up for my FREE 30 minute VA training. Get your behind-the-scenes peek at how I started my virtual assistant business and replaced my full-time salary with no prior experience, seven months pregnant with a 1.5 year old running around!   Get instant access now >>  https://aubreemalick.com/freetraining    Join the Freelancer to CEO Podcast Community on Facebook    If you found value in today's episode, I would love it if you shared this in your Instagram stories! Help us spread the message to more freelancers who are ready to step into the CEO role!    Connect with me on Instagram: @aubreemalick

Go online to PeerView.com/KTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you fully prepared to safely integrate BCMA-targeting options into the care plan for your relapsed/refractory multiple myeloma (MM) patients, including treatment with antibodies, bispecific agents, and CAR-T cell therapy? Find out in this expert-led MasterClass and Case Forum recorded at the Annual Hematology Meeting. Watch our experts as they offer learners guidance on the “road to remission” in MM, and hear how recent advances with BCMA-targeted therapies can directly lead to enhanced outcomes in the most challenging treatment settings. Throughout, the experts also provide case-based guidance on therapy selection with BCMA antibodies and CAR-T therapy, and illustrate how evidence-based practice can optimize delivery of care in pretreated disease. Get on the “road to remission” for your patients, and receive CME/MOC credit today! Upon completion of this activity, participants should be better able to: State the current evidence and rationale that support the treatment roles of novel BCMA-targeting platforms, including antibody-drug conjugates, bispecifics, and CAR-T therapy, in relapsed/refractory disease; Select personalized, evidence-based regimens with novel anti-BCMA options based on patient preference, disease prognosis, and functional status, among others; and Develop strategies for addressing practical aspects of BCMA-targeted therapy in RRMM, including issues related to dosing/scheduling, patient counseling, and unique safety considerations such as cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.

EP 95. Quizzes! Online business growth strategist and trained quiz funnel expert, Helen Munshi, explains how to create quiz funnels to help attract new leads, engage existing customers, and gain incredible data insights to inform your brand storytelling content.    (free) JOIN Marketing With Empathy's Facebook community to connect and network with other brand storytelling strategists: https://urlgeni.us/facebook/mwec    VIEW SHOW NOTES: https://www.podpage.com/marketing-with-empathy/blog/quizzes-to-attract-engage-customers-helen-munshi-episode-95/   (free) 3 WAYS TO IMPROVE YOUR CONTENT STRATEGY THIS YEAR: https://view.flodesk.com/pages/6161f93cc71e8685f183c63e     Learn more about your ad choices. Visit megaphone.fm/adchoices

जुए के नाम से चिढ़ने वाले वाले एक व्यक्ति के दोसों के उकसाने पर दिवाली के दिन जुआ खेलने व हारने की कहानी। लेखक - विश्वम्भरनाथ शर्मा 'कौशिक' Writer - Vishwambharnath Sharma 'Koushik' स्वर - समीर गोस्वामी Narration - Sameer Goswami https://kahanisuno.com/ http://instagram.com/sameergoswami_kahanisuno https://www.facebook.com/kahanisuno/ http://twitter.com/goswamisameer/ https://sameergoswami.com

In today's episode of Money Talkies, once again we speak to the amazing Helen Munshi. Helen is an online business growth strategist and a trained quiz funnel expert with over a decade of experience. She helps entrepreneurs generate consistent high quality leads using the magic of online quizzes. And today she's teaching us how to build a list of hungry buyers using a quiz. Let's find out! Connect with Helen here: Website: https://helenmunshi.com/ Instagram: https://www.instagram.com/helenmunshi/ Facebook: https://www.facebook.com/TheStartUpStudioHM/ LinkedIn: https://helenmunshi.com/ Ready to rewrite your money story? Register to my Five Day Millionaire Mindset Makeover Workshop here: https://www.abundancemindsetmakeover.com/ Visit our website for more information: http://gullkhan.com/

Today we're on another episode of our Friday Feature where we talk with astounding entrepreneurs and their success stories. In today's episode we're speaking to Helen Munshi. Helen is an online business growth strategist and a trained quiz funnel expert with over a decade of experience. She helps entrepreneurs generate consistent high quality leads using the magic of online quizzes. And today we're finding out how she changed her life by changing her mindset. Let's find out! Connect with Helen here: Website: https://helenmunshi.com/ Instagram: https://www.instagram.com/helenmunshi/ Facebook: https://www.facebook.com/TheStartUpStudioHM/ LinkedIn: https://helenmunshi.com/ Ready to rewrite your money story? Register to my Five Day Millionaire Mindset Makeover Workshop here: https://www.abundancemindsetmakeover.com/ Visit our website for more information: http://gullkhan.com/

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

This summer our Equipping in Ten episodes are interviews with some of our Men in the Arena National Team Captains. We have asked them to write a blog to go with their interview as well.  Kai is a former U.S. Marine Corps infantry officer and federal law enforcement officer. He still works for the government in the field of training and education. He and his wife Sheri have been married for over 20 years. They live on Saint Simons Island in Georgia. Kai serves on the Men in the Arena Board of Directors Get Your Copy Now! of Tell Them, What Great Fathers Tell Their Sons and Daughters www.meninthearena.org Men in the Arena Books and Swag Support the Podcast